Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function
نویسندگان
چکیده
منابع مشابه
Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function.
OBJECTIVES The goal of this study was to evaluate platelet function and to preliminarily assess the clinical safety of sequential treatment with tirofiban or eptifibatide followed by abciximab in patients undergoing percutaneous coronary intervention (PCI). BACKGROUND An increasing number of acute coronary syndrome (ACS) patients are treated early with tirofiban or eptifibatide. Some later re...
متن کاملRandomized COMparison of Platelet Inhibition With Abciximab, TiRofiban and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes
Background—The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established. Methods and Results—We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban...
متن کاملVariability in extent of platelet function inhibition after administration of optimal dose of glycoprotein IIb/IIIa receptor blockers in patients undergoing a high-risk percutaneous coronary intervention.
The Ultegra Rapid Platelet Function Assay was used to measure the inhibition of platelet aggregation at baseline and 10 minutes and 8 hours after starting therapy in 114 patients undergoing high-risk percutaneous coronary intervention with the planned use of a glycoprotein IIb/IIIa inhibitor. The abciximab-treated patients received a 0.25 mg/kg bolus, followed by a 0.125 microg/kg/min infusion ...
متن کاملAssessment of platelet function in patients receiving tirofiban early after primary coronary intervention
BACKGROUND Following percutaneous coronary intervention, combined antiplatelet therapy is necessary. Platelet function testing (PFT) has prognostic value and may be applied in the risk assessment of acute coronary syndrome. In case of combined antiplatelet therapy, PFT may require special laboratory methods, as different antiplatelet agents may influence test results. MATERIALS AND METHODS Pl...
متن کاملPlatelet inhibition after glycoprotein IIb/IIIa inhibitor therapy.
Inhibitor Therapy To the Editor: In their clinically sound GOLD (AU-Assessing Ultegra) study, Steinhubl et al1 reported striking results concerning the widely variable level of platelet function inhibition achieved with glycoprotein IIb/IIIa (GP IIb/IIIa) antagonists among patients undergoing percutaneous coronary intervention. They also documented the important clinical implications related to...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2001
ISSN: 0735-1097
DOI: 10.1016/s0735-1097(00)01181-5